Compare Apixaban and Vitamin-K Antagonists in Patients With Atrial Fibrillation (AF) and End-Stage Kidney Disease (ESKD) (AXADIA)
A Safety Study Assessing Oral Anticoagulation With Apixaban Versus Vitamin-K Antagonists in Patients With Atrial Fibrillation (AF) and End-Stage Kidney Disease (ESKD) on Chronic Hemodialysis Treatment
Sponsor: Atrial Fibrillation Network
This PHASE3 trial investigates Atrial Fibrillation and End-stage Kidney Disease and is currently completed. Atrial Fibrillation Network leads this study, which shows 13 recorded versions since 2017 — indicating substantial longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.
Status Flow
Change History
13 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Sep 2022 — Jul 2024 [monthly]
Completed PHASE3
Status: Recruiting → Completed
-
May 2021 — Sep 2022 [monthly]
Recruiting PHASE3
-
Jan 2021 — May 2021 [monthly]
Recruiting PHASE3
▶ Show 8 earlier versions
-
Nov 2020 — Jan 2021 [monthly]
Recruiting PHASE3
-
Sep 2019 — Nov 2020 [monthly]
Recruiting PHASE3
Status: Unknown Status → Recruiting
-
Aug 2019 — Sep 2019 [monthly]
Unknown Status PHASE3
Status: Recruiting → Unknown Status
-
Jun 2018 — Aug 2019 [monthly]
Recruiting PHASE3
-
Feb 2018 — Jun 2018 [monthly]
Recruiting PHASE3
-
Aug 2017 — Feb 2018 [monthly]
Recruiting PHASE3
Status: Not Yet Recruiting → Recruiting
-
May 2017 — Aug 2017 [monthly]
Not Yet Recruiting PHASE3
-
Jan 2017 — May 2017 [monthly]
Not Yet Recruiting PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Atrial Fibrillation Network
- Bristol-Myers Squibb
- Pfizer
For direct contact, visit the study record on ClinicalTrials.gov .